Latest news for Carawine Resources (OTC:CAWRF) Stock

Carawine Resources Ltd is a mineral exploration company. It focuses on the exploration and development of gold, copper, cobalt, and base metal within Western Australia and Victoria. The company has five exploration projects: the Jamieson project, Tropicana North Project, Oakover project, Paterson project, and Fraser Range project.

Carawine Resources Ltd

Susquehanna analyst Joseph Stauff maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Positive and lowers the price target from $49 to $47.

News

Price Target

Analyst Ratings

DKNG

Susquehanna Maintains Positive on DraftKings, Lowers Price Target to $47

<a href="https://www.globenewswire.com/Tracker?data=PYYt3BoHcKFAz5beivylzs5pdrMJaIDXS-FdLrSTOOQ-KKFm2XwNYGfzCMW9e95HgcGKZj0BfptprYehiAQ_gLkU8W_P-EZgmTxF4Ty_bW1E2qkfo17wGbhrk0IhXcuaypwlPrn6Z05Dwy_zOUlDxrMILr39PuJ4Zn6tLhO-lZagIC0J3wYvF5GdVO_x-23GN1EyXkRPUIRWuWia106TKmKNVAYrZMIM2EBALxKnjYf54GLOgtrMonL7n87BK_XruRAjqHwVf-JsKrp_e5Ys6keSvsrZl9a_uiqNeI4Gt9a5FkAvMJXJbRmg3QXwztZUaf7w-jA0m_Pwiojb5MnNSs9ACw37cQ5eSfDNaPY3hR9w3LtIag_5mdV1tUw8_THf">Notified</a>, a globally trusted technology partner for investor relations and public relations professionals, and <a href="https://www.globenewswire.com/Tracker?data=XbMcxup_9Dx1_3fkDd9SvCD-ouDHFT0MsMF4ZF3qpQXpr0KWc1NCW4DEyvjWARCHc9xVlLpgJMCPGza2z3vxqgwN8vHT_atvZZG81agEosZmm8Tz2zyrTknzfJS_SiK2hQSLYSNqWtCYD25gBmZqyR-Wz5PHRwhdyVS1fiI9T3zD3tDPLeUj840Saq06A-hwabQHj_TmZqx1Nsz4Y_bmwlrtponC-RyG5EMVLqPreYImh5O5EGMY4lrS0LdQTXJcmIz4FVyhDJ0Us9_nEtwMfcdX38W7jLLvsLljB7ztiPWyWV163oW35ABo1B_0nc06RhaSyROYYoziiRi-rMgPS2ayV9ufEs9E-xPHo6bsHK5AoNurwAQTdXnSKfbevBwxzOtwHJRBHGCdYJ3bmzvvQA==">CLEAR</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>), the secure identity company, today announced an exclusive agreement to integrate CLEAR&#xAE; identity verification technology into Notified's <a href="https://www.globenewswire.com/Tracker?data=POv0YtU99Fs6Y37yN7t7nqpFYuFthJJGAeH-O8EBrahzu8kyA6Qa5-JHTIwHh1ZDHx7h3Gk5v9SG_qfuczfLn7be2XzzgkAYmuGabvYbUU6JzJ5rU543GRuAknpCffWB586ZDmrPU_xa62tFtWZByq-Tk5x34czNcFrJCMk9i7pwMIDF8HVrl5hyU8-ZYRV60Idb9PymNQGBOT7Q_9_FiaMt19dFSgBHcDA1G4fO9L24btYRlRW8Aa64Ni8fHbhqPRSPxfm99PpUzU-JxChb8Ebuo_h6HQYcK-hzhGK9dJl1PidQr7n35d58Z7malZDWAGccGD6VY7qhPoFn7rT50MMuqt_jNi48lKXiZIeQiH4EE5Q4tBwu0hnlLQsCNwURtckL0W-oUrkr_b1wN0peJw==">GlobeNewswire</a>&#xAE; press release distribution platform. This collaboration will enhance trust in financial, regulatory and corporate communications by confirming that press releases are issued by a verified individual.

Notified And CLEAR Bring Identity Verification To GlobeNewswire Press Releases

Sapphire Reserve&#xAE;
<ul>
<li>Cardmembers with active, free DashPass memberships will continue to receive the benefit through December 31, 2027.
<ul>
<li>New and existing Sapphire Reserve cardmembers who have not yet activated the DashPass benefit can enroll to receive a complimentary DashPass benefit through December 31, 2027, or a minimum of 12 months, dependent upon the activation date.</li>
</ul>
</li>
<li>New: Cardmembers with an activated Sapphire Reserve DashPass membership now receive two promos of up to $10 off each calendar month at checkout on grocery, convenience, or other non-restaurant orders on DoorDash.</li>
<li>Sapphire Reserve cardmembers will continue to receive the existing $5 monthly DoorDash in-app credit through January 31, 2025. Beginning February 1, 2025, cardmembers will receive a new monthly benefit for $5 off restaurant orders on DoorDash.</li>
</ul>
Sapphire Preferred&#xAE;
<ul>
<li>Cardmembers with active, free DashPass memberships will continue to receive the benefit through December 31, 2027.
<ul>
<li>New and existing Sapphire Preferred cardmembers who have not yet activated the DashPass benefit can enroll to receive a complimentary DashPass benefit through December 31, 2027, or a minimum of 12 months, dependent upon the activation date.</li>
</ul>
</li>
<li>New: Cardmembers with an activated Sapphire Preferred DashPass membership now receive one promo of up to $10 off each calendar month at checkout on one grocery, convenience, or other non-restaurant order on DoorDash.</li>
</ul>
Freedom&#xAE; and Slate&#xAE;
<ul>
<li>Cardmembers who have not used the Chase DashPass benefit have until January 31, 2025, to enroll in the current benefit – three months of free membership followed by nine months of discounted DashPass.&#x2A;</li>
<li>New: Starting February 1, 2025, new enrollees will receive six free months of DashPass.&#x2A;</li>
<li>New: Cardmembers who have activated a Freedom or Slate DashPass membership now receive one promo of up to $10 off each quarter at checkout on one grocery, convenience, or other non-restaurant order on DoorDash.</li>
</ul>

DASH

Chase Extends DashPass Membership For Eligible Cardmembers Through 2027; New Grocery And Convenience Benefits Added; Chase Sapphire And Other Eligible Cardmembers To Receive Recurring Benefits On Orders From Over 150,000 Stores On DoorDash

Susquehanna analyst Bascome Majors maintains C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) with a Neutral and raises the price target from $90 to $95.

CHRW

Susquehanna Maintains Neutral on C.H. Robinson Worldwide, Raises Price Target to $95

Susquehanna analyst Charles Minervino maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Positive and raises the price target from $220 to $230.

Susquehanna Maintains Positive on Boeing, Raises Price Target to $230

Business&nbsp;Outlook
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
(in millions, except per share data)
</td>
<td colspan="1" rowspan="1">
Current&nbsp;Guidance
</td>
<td colspan="1" rowspan="1">
Prior&nbsp;Guidance
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted diluted earnings per share
</td>
<td colspan="1" rowspan="1">
$0.80&nbsp;-&nbsp;$0.90
</td>
<td colspan="1" rowspan="1">
$0.85&nbsp;-&nbsp;$1.00
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Net capital expenditures
</td>
<td colspan="1" rowspan="1">
$300.0&nbsp;-&nbsp;$350.0
</td>
<td colspan="1" rowspan="1">
$350.0&nbsp;-&nbsp;$400.0
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>

Earnings

Guidance

SNDR

Schneider National Cuts Its 2024 Adj. EPS Guidance From $0.85-$1.00 To $0.80-$0.90 Vs. $0.81 Est.

LILA

TIGO

Under The Terms Of The All-Stock Agreement, Liberty Latin America And Its Minority Partner In Costa Rica Will Hold An ~86% Interest And Millicom 14% In The Joint Operations

Tech giant Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is scheduled to announce its fiscal year 2024 third-quarter results after the market closes on Thursday. <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39665665/apple-microsoft-meta-google-stocks-hit-52-week-highs-which-is-the-best-investment">Investors have resiliently held onto the stock </a>amid the company&#8217;s soft patch, precipitated by slowing global economic growth that tempers the demand outlook.
Apple&#8217;s Key Q3 Numbers To Watch: The June quarter is seasonally slow for Apple, coming ahead of the back-to-school and holiday quarters. Customers also push back purchases in anticipation of the newest hardware products that typically roll out in late September or early October.
Cupertino entered the third quarter, having reported revenue declines for five quarters in the past six. The company is widely expected to report year-over-year growth in the top and bottom lines. Here are the consensus estimates and the prior-period numbers:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td></td>
<td>Q3&#8217;24 Consensus&#x2A;</td>
<td>Q3&#8217;23</td>
<td>Q2&#8217;24</td>
</tr>
<tr>
<td>Revenue</td>
<td>$84.53B</td>
<td>$81.80B</td>
<td>$90.75B</td>
</tr>
<tr>
<td>Non-GAAP EPS</td>
<td>$1.35</td>
<td>$1.26</td>
<td>$1.53</td>
</tr>
<tr>
<td>Gross margin</td>
<td>N/A</td>
<td>44.26%</td>
<td>46.58%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">&#x2A;according to Benzinga Pro data</figcaption></figure>
Wedbush&#8217;s Daniel Ives said he expects mostly in-line headline numbers for the June quarter. &#8220;The Street is viewing this June quarter as just the warm-up to the main historical event for Cupertino which is the AI-driven supercycle beginning with iPhone 16 set to launch in mid-September,&#8221; he said
See Also: <a href="https://www.benzinga.com/money/best-consumer-discretionary-stocks">Best Consumer Discretionary Stocks</a>
Apple&#8217;s Key Businesses &#8211; What To Expect: The flagship iPhone contributes a little over 50% to Apple&#8217;s top line. Estimates by market researcher Canalys <a href="https://www.canalys.com/newsroom/the-global-smartphone-market-Q2-2024">show</a> that Apple shipped 45.6 million units in the June quarter, marking a 6% year-over-year growth. This was among the slowest growth rate among the other major global smartphone manufacturers, next only to Samsung.
Most Chinese makers reported a double-digit growth rate, led by Xiaomi Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>). Apple&#8217;s smartphone market share slipped a percentage point year-over-year. The product mix assumes importance as it would decide the fate of revenue contribution from the product.
The PC market survey by IDC bodes well for Apple&#8217;s Mac shipments. The tech giant reported the fastest year-over-year growth among major manufacturers and was the fourth biggest maker, shipping 4.4 million units during the quarter. Apple&#8217;s PC shipments climbed 20.8% year-over-year compared to 3.7% for market leader Lenovo, 1.8% for HP and a negative 2.4% for Dell.
Ives expects the Services business to outdo expectations.
Look Ahead: The consensus estimates for Apple&#8217;s September quarter and full year are as follows:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td></td>
<td>Q4 Consensus</td>
<td>Change (Y-o-Y)</td>
<td>FY24 Consensus</td>
<td>Y-o-Y Change</td>
</tr>
<tr>
<td>EPS</td>
<td>$1.56</td>
<td>+6.85%</td>
<td>$6.62</td>
<td>+8.00%</td>
</tr>
<tr>
<td>Revenue</td>
<td>$93.39B</td>
<td>+4.4%</td>
<td>$387.96B</td>
<td>+1.22%</td>
</tr>
</tbody>
</table>
</figure>
Ives is very bullish about Apple&#8217;s long-term. &#8220;In our view, the renaissance of growth coming to Apple is still very underestimated by the Street and we see a $4 trillion market cap for Cupertino in 2025,&#8221; he said.
Wedbush has an Outperform rating and a $275 price target for the stock.
Recently, Morgan Stanley&#8217;s Erik Woodring named Apple the firm&#8217;s Top Pick and raised the price target for the stock from $216 to $273. The analyst expects Apple Intelligence to benefit more than just iPhone shipments, given users will need to buy an iPhone 15 Pro/Pro Max or newer models to use Apple Intelligence. This, according to the analyst, will positively influence the product mix and nudge ASPs.
Apple Stock: For the year-to-date period, <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">Apple stock </a>has added over 15.50%, comparable with the SPDR S&amp;P 500 ETF Trust&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) 16.62% gain and Invesco QQQ Trust&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) 15.37% advance.
In premarket, the stock rose 1% to $224.29, according to Benzinga Pro data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39269940/apples-ai-breakthroughs-at-wwdc-2024-lead-to-higher-iphone-sales-projections-by-gol">Apple&#8217;s AI Breakthroughs At WWDC 2024 Lead To Higher iPhone Sales Projections By Goldman Sachs</a></li>
</ul>
Image Via Shutterstock

Equities

Previews

Markets

Tech

Trading Ideas

AAPL

XIACF

Will Apple Lay The Case For Easing Into AI Superhighway? Analysts Expect iPhone Maker's Q3 Results To Signal Inflection In Topline Growth

Susquehanna analyst James Friedman maintains AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) with a Positive and lowers the price target from $16 to $14.

AVDX

Susquehanna Maintains Positive on AvidXchange Holdings, Lowers Price Target to $14

On Wednesday, ALX Oncology Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) released topline data from its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g40080441/alx-oncology-reports-topline-data-from-aspen-06-phase-2-trial-demonstrating-evorpacept-improves-tu" rel="noreferrer noopener">Phase 2 ASPEN-06 clinical trial</a>.
ASPEN-06 is evaluating evorpacept in combination with trastuzumab, Cyramza (ramucirumab), and paclitaxel (collectively, TRP) against TRP alone for HER2-positive gastric/GEJ cancer, where all patients had received an anti-HER2 agent in prior lines of therapy.
The ASPEN-06 study is testing a new treatment combination for advanced stomach and gastroesophageal cancer in patients who have already undergone other treatments. This combination includes a drug named evorpacept, added to a standard therapy mix.
Results so far show that this new combination helps patients respond better and for a longer duration compared to the standard therapy alone.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37566272/alx-oncology-has-elevated-valuation-analyst-downgrades-stock-highlights-need-for-de" rel="noreferrer noopener">ALX Oncology Has &#8216;Elevated Valuation&#8217; &#8211; Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer</a>.
In the full intent-to-treat population (N=127), the addition of evorpacept to TRP demonstrated an overall response rate (ORR) of 40.3% compared to the TRP control ORR of 26.6%.
The company released prespecified interim Phase 2 data from its ASPEN-06 trial in October 2023.
The data showed a confirmed overall response rate (ORR) of 52% for evorpacept in combination with trastuzumab + Cyramza + paclitaxel compared to 22% for the control group of <a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35057455/why-cancer-focused-alx-oncology-stock-gained-over-100-today" rel="noreferrer noopener">trastuzumab + Cyramza + paclitaxel</a>.
In patients with fresh HER2-positive biopsies (n=48), evorpacept plus TRP demonstrated an ORR of 54.8% compared to 23.1% for the TRP control.
The median duration of response (DOR) in the evorpacept arm was 15.7 months compared to the TRP control of 7.6 months.
Secondary endpoints of progression-free survival (PFS) and overall survival (OS) were immature at the time of analysis.
Evorpacept, in combination with TRP, was generally well tolerated and consistent with TRP control.
&#8220;By meeting our clinically meaningful and pre-specified threshold of greater than 10% difference in response between the evorpacept treatment and control arms, these new data validate the mechanism of action and potential clinical utility of evorpacept for patients. Notably, this is now the first CD47 blocker to demonstrate clinical benefit and a well-tolerated safety profile in a randomized trial,&#8221; said Sophia Randolph, chief medical officer at ALX Oncology.
The FDA has granted Fast Track designation to evorpacept for the second-line treatment of patients with HER2-positive gastric or GEJ carcinoma. The FDA and European Commission have also granted Orphan Drug Designation for this indication.
Price Action: ALXO stock is down 34.40% at $3.15 during the premarket session at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40079001/pfizers-diverse-portfolio-and-strong-execution-earn-analyst-praise-despite-patent-c" target="_blank" rel="noreferrer noopener">Pfizer&#8217;s Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns</a>.</li>
</ul>
Don&#8217;t miss the opportunity to dominate in a volatile market at the <a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Benzinga SmallCAP Conference</a> on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you&#8217;re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!

Biotech

Health Care

Movers

General

ALXO

Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients

JP Morgan analyst Doug Anmuth maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Overweight and raises the price target from $480 to $610.

JP Morgan Maintains Overweight on Meta Platforms, Raises Price Target to $610

Available Now For Men, Children, Agricultural Professionals, Construction Workers, Outdoor Enthusiasts, and Fashion-Minded Individuals

Skechers and John Deere Launch New Collection Combining Heritage and Comfort Technologies

Unity Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNTY#NASDAQ">UNTY</a>), parent company of Unity Bank, announced that its Board of Directors has approved a new Share Repurchase Program. Under this new program, the Company may repurchase up to 500,000 shares, or approximately 5.0% of its outstanding common stock. The timing and amount of any repurchases will depend on a number of factors, including the availability of stock, general market conditions, the trading price of the stock, alternative uses for capital, and the Company's financial performance.

Buybacks

UNTY

Unity Bancorp Announces New Share Repurchase Program Of Up To 500K Shares, Or ~5% Of Its Outstanding Common Stock

WIIM

RBLX

Roblox shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.

HC Wainwright &amp; Co. analyst Sean Lee reiterates Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy and maintains $20 price target.

Reiteration

ATEC

HC Wainwright & Co. Reiterates Buy on Alphatec Holdings, Maintains $20 Price Target

Davis Food &amp; Drug partners with Instacart to enhance shopping experience with AI-powered smart carts
SAN FRANCISCO and VERNAL, Utah, Aug. 1, 2024 /PRNewswire/ -- Davis Food &amp; Drug, a prominent three-store grocery chain in Utah, and Instacart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>), the leading grocery technology company in North America, today announced a new partnership to replace the majority of its traditional shopping carts with Instacart's artificial intelligence-powered (AI) smart carts at all Davis Food &amp; Drug locations in Utah in the coming months.&nbsp;
 &nbsp;

CART

Davis Food & Drug Announces New Partnership To Replace The Majority Of Its Traditional Shopping Carts With Instacart's AI-Powered Smart Carts At All Davis Food & Drug Locations In Utah In The Coming Months

Liberty Latin America And Millicom Agree To Combine Operations In Costa Rica

Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.18 by 16.67 percent. This is a 53.33 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $1.316 billion which missed the analyst consensus estimate of $1.352 billion by 2.65 percent. This is a 2.30 percent decrease over sales of $1.347 billion the same period last year.

Earnings Beats

Earnings Misses

Schneider National Q2 2024 Adj. EPS $0.21 Beats $0.18 Estimate, Sales $1.316B Miss $1.352B Estimate

In the first four weeks of the application process, only 43 applications for cannabis cultivation associations have been submitted in North Rhine-Westphalia (NRW), a state in Western Germany. With more than 18 million inhabitants, NRW is the most populous state in Germany.
However, nearly all applications are incomplete, <a href="https://aussiedlerbote.de/en/in-four-weeks-43-cannabis-clubs-apply/" target="_blank" rel="noreferrer noopener">writes </a>ASB Zeitung. Upon completing the applications, the authorities have about three months to either approve or deny them.
Previous statements from the Ministry of Health implied the state could permit up to 3,000 cultivation licenses (allowing one cannabis club per 6,000 residents). Then again, the clubs must satisfy numerous requirements. For example, they must be located at least 200 meters from schools and other youth facilities and playgrounds. A club can have a maximum of 500 adults who have lived in Germany for at least six months.
So far, only a fraction of applications have been completed and in some parts of Germany, even fewer have been submitted. In Berlin, only 14 applications have been submitted, as per the new agency DPA, and as <a href="https://cannabizeu.com/friedrich-merz-wants-to-ban-cannabis-again/" target="_blank" rel="noreferrer noopener">reported</a> by CannaBizEu. To make things even more complicated applications cannot be processed if a corresponding regulation is missing.
In Bavaria, people wanting to cultivate cannabis must prove that they are trained in counseling and prevention. Official training by the Center for Prevention and Health Promotion is scheduled for September. Six clubs in Saarland are also waiting for approval due to the lack of training.
When partial cannabis legalization <a href="https://www.benzinga.com/markets/cannabis/24/04/38023610/heres-what-you-need-to-know-about-weed-legalization-in-germany-that-just-took-effect" target="_blank" rel="noreferrer noopener">took effect in Germany on April 1</a>, it allowed adults over 18 to possess up to 25 grams of dried cannabis and groe up to three plants at home. One of the biggest breakthroughs under the law is that medical marijuana is essentially <a href="https://www.benzinga.com/markets/cannabis/24/07/39830117/medical-marijuana-regulated-as-ibuprofen-is-one-of-the-biggest-breakthroughs-of-germanys-cannabi" target="_blank" rel="noreferrer noopener">regulated like ibuprofen</a>. Cannabis clubs became legal on July 1, 2024, and the first such marijuana social club <a href="https://www.benzinga.com/markets/cannabis/24/07/39690787/first-cannabis-club-in-germany-opens-lawmaker-says-it-will-stem-illicit-marker-cops-say-the-oppo" target="_blank" rel="noreferrer noopener">opened its doors on July 8</a> in Lower Saxony.
See Also: <a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/07/40015799/german-cannabis-producer-demecan-can-grow-unlimited-amounts-of-marijuana-sees-strong-revenue-gro" rel="noreferrer noopener">German Cannabis Producer DEMECAN Becomes First Company ReceivesCultivation License Under Legalization Program, Sees Strong Revenue Growth (Updated)</a>
<h2 class="wp-block-heading">Christian Democrat Leader Seeks To Reverse Cannabis Law</h2>
Four months after marijuana was partially legalized in Germany, Christian Democratic Union (CDU) leader, Friedrich Merz is blaming weed for increased rates of criminal activity. He&#8217;s vowed to reverse the cannabis law if his party wins next year's federal elections, <a href="https://cannabizeu.com/friedrich-merz-wants-to-ban-cannabis-again/" target="_blank" rel="noreferrer noopener">writes</a> CannaBizEu.
"The legalization of cannabis is currently leading to an explosion in drug-related crime and organized criminal activity, including gang wars that we can barely imagine," Merz <a href="https://www.t-online.de/nachrichten/deutschland/innenpolitik/id_100457190/cdu-chef-friedrich-merz-will-cannabis-bei-regierungsuebernahme-verbieten.html" target="_blank" rel="noreferrer noopener">told</a> Welt am Sonntag.
Speaking of crime rates, Merz says an alleged gang war in involving German and Dutch gangs and about 300 kilograms of missing marijuana. "The Dutch, who have tolerated cannabis consumption for years, are shocked by what is happening in Germany right now," Merz told the German outlet. "Therefore, as in other areas, quick action is required after a government change."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/40058034/medical-marijuana-patients-in-germany-benefit-from-50-price-reduction-thanks-to-legalization-new" target="_blank" rel="noreferrer noopener">Medical Marijuana Patients In Germany Benefit from 50% Price Reduction Thanks To Legalization, New Report</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/40017479/medical-marijuana-to-be-more-widely-reimbursed-in-germany-hemp-bill-attracts-investors-and-more-" target="_blank" rel="noreferrer noopener">Medical Marijuana To Be More Widely Reimbursed In Germany, Hemp Bill Attracts Investors And More Cannabis News</a></li>
</ul>
Photo: Courtesy of Plateresca via Shutterstock

Cannabis

Eurozone

Germany's Cannabis Clubs Face Setbacks Amid Reg Hurdles, Christian Democrat Leader Wants To Reverse Marijuana Law

JP Morgan analyst Brian Ossenbeck upgrades C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) from Neutral to Overweight and raises the price target from $87 to $110.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Carawine Resources

News

Latest news for Carawine Resources (OTC:CAWRF) Stock